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Abstract The quinoline-based tertiary amine dibucaine has
been shown to bind the membrane skeletal protein spectrin
with a dissociation constant of 3.5U1035 M at 25‡C. Such
binding is detected by monitoring the quenching of the trypto-
phan £uorescence intensity with increasing concentrations of
dibucaine only and not with the benzene-based local anesthetics
procaine, tetracaine and lidocaine. Binding of dibucaine also
indicated changes in the tertiary structure of spectrin indicated
by a circular dichroism spectrum in the near-UV region due to
absorption of the aromatic side chains. The thermodynamic pa-
rameters associated with the binding indicated the interaction of
dibucaine and spectrin to be enthalpy-driven and insensitive to
an increase in the ionic strength of the bu¡er.
, 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Tertiary amine local anesthetics cause anesthesia by block-
ing nerve transmissions via state-dependent binding of vol-
tage-gated Naþ channels. There are two major models of
anesthetic action. The ¢rst of these, called the lipid hypoth-
esis, ascribes the e¡ect to physical alterations of the lipid
bilayer upon binding of the anesthetic to it. The second, called
the protein hypothesis, explains it in terms of direct speci¢c
interaction of local anesthetic molecules with proteins [1^5].
Local anesthetics have been shown to interact with many
membrane-associated proteins other than the primary target
Naþ channel. Those include the acetylcholine receptor [6],
cytochrome oxidase [7] and the F1 ATPase [8,9] and band 3
of erythrocytes [10]. In addition it has been shown that the
denaturation temperature of Ca2þ-ATPase of the sarcoplas-
mic reticulum is lowered slightly by dibucaine and tetracaine,
indicating an interaction between local anesthetics and the
membrane-bound Ca2þ-ATPase [11,12]. More studies have
been done examining the e¡ects of local anesthetics on protein
structure and activity. Dibucaine and tetracaine inhibited the
activation of mitogen-activated protein kinase mediated by
calcium channels [13]. Procaine, tetracaine and dibucaine
caused inhibitions of dog kidney Naþ,Kþ-ATPase activity
[14] and G protein-coupled receptor signaling [15]. Local anes-
thetics were also found to a¡ect phospholipase D activity in
di¡erentiated human leukemic cells [16] and brain microtubule
assembly [17].
Spectrin is the major constituent protein of the erythrocyte
cytoskeleton that forms a ¢lamentous network on the cyto-
plasmic face of the membrane. To establish the planar net-
work, spectrin interacts with a large number of proteins such
as actin, adducin, ankyrin and protein 4.1. In addition to
those proteins spectrin binds to fatty acids, phospholipids
and a few other hydrophobic ligands. Spectrin is composed
of the two largest known, evolutionarily related polypeptide
chains, K-subunit (V240 kDa) and L-subunit (V220 kDa),
both of which are non-covalently associated in an antiparallel
‘side-to-side’ manner to form a two-stranded, highly elon-
gated, worm-like heterodimer [18^20]. The heterodimers fur-
ther self-associate in a ‘head-to-head’ fashion to form tet-
ramers, the dominant form in vivo. In an earlier work we
have studied the interaction of the quinoline-based local anes-
thetic dibucaine, with small unilamellar vesicles made of phos-
pholipids containing di¡erent mole percentages of cholesterol
indicating di¡erences in the microenvironment of dibucaine in
the presence and absence of cholesterol in the bilayer mem-
branes [21]. As a part of our broad objective to understand
the intracellular mode of action of the tertiary amine local
anesthetics we have studied the interaction of dibucaine with
the erythrocyte membrane skeletal protein spectrin, since such
interactions of local anesthetics have been implied to have a
functional association with the Naþ channel [22] and the
transbilayer movement of the anesthetic molecule to the cyto-
plasmic side of excitable membranes is a requirement for anes-
thetic action [23].
In the present study we show a moderately high-a⁄nity
binding between spectrin and the local anesthetic dibucaine
using £uorescence spectroscopy. We also attempt to under-
stand the thermodynamic basis of such a binding of dibucaine
to erythroid spectrin. In addition to the evaluation of the
binding a⁄nities and associated thermodynamic parameters
we have employed circular dichroism (CD) spectroscopy to
throw light on the structural basis of recognition and confor-
mational changes of the membrane skeletal protein spectrin.
2. Materials and methods
Dibucaine hydrochloride, Tris, phenylmethylsulfonyl £uoride
(PMSF), dithiothreitol (DTT), and EDTA were purchased from Sig-
ma (St. Louis, MO, USA). Deionized water, twice distilled on quartz,
was used for preparing solutions and bu¡ers. Stock solution of dibu-
caine was prepared in water and its concentration was determined by
absorbance measurement on a Shimadzu UV-2101PC spectrophotom-
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eter, using a molar extinction coe⁄cient of 4400 M31 cm31 at 326 nm
[24]. The CD spectra were recorded in a Jasco 720 spectropolarimeter.
CD spectra in the range 200^250 nm were recorded in a cylindrical
cuvette of 1 mm pathlength. All spectra are the average of ¢ve runs.
For measurements in the near-UV range (250^310 nm) a rectangular
quartz cuvette of 1 cm pathlength was used. Each spectrum was sub-
tracted from the bu¡er baseline and smoothed within the permissible
limits using the in-built software of the instrument as described earlier
[25].
White ghosts from goat blood were prepared by hypotonic lysis in
5 mM phosphate, 1 mM EDTA containing 20 Wg/ml PMSF at pH 8.0
and spectrin dimers were puri¢ed following published protocols elab-
orated earlier [25,26]. Spectrin extraction was done by resuspending
the erythrocyte ghosts in 20 vol of spectrin removal bu¡er (0.2 mM
sodium phosphate, 0.1 mM EDTA, 0.2 mM DTT, 20 Wg/ml PMSF,
pH 8.0), and incubating at 37‡C for 30 min. The crude spectrin was
collected in the supernatant after centrifugation and was puri¢ed after
concentration by 30% ammonium sulfate precipitation according to
the method of Gratzer [26]. Spectrin was stored in the bu¡er contain-
ing 5 mM phosphate, 20 mM KCl, 1 mM EDTA, pH 8.0 containing
0.2 mM DTT. The protein was dialyzed extensively against the bu¡er
containing 20 mM Tris^HCl, 50 mM NaCl, pH 7.4 to remove DTT
before all £uorescence experiments. The purity of the preparation was
checked by 7.5% SDS^PAGE under reducing conditions. The puri¢ed
protein showed the characteristic spectrin dimer (K-chain of apparent
molecular mass ofV240 kDa and L-chain ofV220 kDa) upon stain-
ing the gel with Coomassie blue. Spectrin concentrations were deter-
mined spectrophotometrically from an absorbance of 10.7 at 280 nm
for 1% spectrin solution [26].
2.1. Fluorescence measurements
Steady-state £uorescence was measured in a Fluoromax 3 spectro-
£uorometer using a 1 cm pathlength quartz cuvette. The bu¡er used
in the present study contained 20 mM Tris^HCl, 50 mM NaCl, pH
7.4. Small aliquots of an aqueous stock solution of dibucaine hydro-
chloride were added to 0.1 WM spectrin for £uorescence measurements
using excitation at 295 nm and slits with bandpasses of 5 nm for both
excitation and emission channels. Spectrin-free bu¡er containing dif-
ferent concentrations of dibucaine was used as reference blanks in all
£uorescence measurements. Fluorescence intensities were corrected for
the inner ¢lter e¡ect due to absorption of the spectrin and dibucaine,
when absorbance, at both excitation and emission wavelengths, of the
samples exceeded 0.05 [27]. All measurements were performed at
25‡C, unless otherwise mentioned, with multiple sets (three to ¢ve)
of samples.
2.2. Evaluation of binding constants
Any change in the £uorescence emission intensity of spectrin
(Vex = 295 nm, Vem = 340 nm) upon the progressive addition of dibu-
caine was measured to evaluate the binding constant. Results from
£uorescence titrations were analyzed by the following methods. Ap-
parent dissociation constant (Kd = 1/Kapp) was determined using non-
linear curve ¢tting analysis (Eqs. 1 and 2) based on the following
equilibrium:
Dbþ Sp ¼ Db3Sp
where Db represents dibucaine and Sp represents spectrin. All exper-
imental points for binding isotherms were ¢tted by least-square anal-
ysis.
Kd ¼ Cs3ðvF=vFmaxÞCsW½Cd3ðvF=vFmaxÞ CsðvF=vFmaxÞCs ð1Þ
CsðvF=vFmaxÞ23ðCs þ Cd þ KdÞðvF=vFmaxÞ þ Cd ¼ 0 ð2Þ
vF is the change in £uorescence emission intensity at 340 nm
(Vex = 295 nm) for each point of the titration curve, vFmax is the
same parameter when the ligand is totally bound to spectrin, Cd is
the concentration of dibucaine, Cs is the initial concentration of spec-
trin and Kd is the apparent dissociation constant. A double reciprocal
plot was used for determination of vFmax using:
1=vF ¼ 1=vFmax þ Kd
vFmaxWðCd3CsÞ ð3Þ
The linear double reciprocal plot of 1/vF against 1/(Cd3Cs) is ex-
trapolated to the ordinate to obtain the value of vFmax from the
intercept as described earlier [25]. The approach is based on the as-
sumption that emission intensity is proportional to the concentration
of the ligand and CdECs, i.e. when ligand concentration is in large
excess over the spectrin concentration. The apparent binding constant
(Kapp = 1/Kd) was also determined from the concentration of dibucaine
corresponding to 50% of the total amplitude of change in £uorescence
intensity of spectrin. An estimate of the stoichiometry of dibucaine
binding to spectrin was obtained from the intersection of two straight
lines obtained from the least-square ¢t plot of normalized increase in
£uorescence intensity against the ratio of input concentrations of di-
bucaine and spectrin.
2.3. Evaluation of thermodynamic parameters
Thermodynamic parameters, vG (free energy), vH (heat content)
and vS (entropy) were evaluated from the following equations:
lnKapp ¼ 3ðvH=RTÞ þ ðvS=RÞ ð4Þ
vG ¼ vH3TvS ð5Þ
where R and T are the universal gas constant and absolute temper-
ature, respectively. The apparent binding constant (Kapp = 1/Kd) was
measured at four di¡erent temperatures to evaluate vH and vS from
the slope and the intercept in a plot of lnKapp against 1/T.
3. Results
The change in tryptophan £uorescence of spectrin indicates
the association of the protein with dibucaine. Fig. 1 shows the
progressive quenching of tryptophan £uorescence of spectrin
upon the addition of increasing concentrations of dibucaine,
thereby indicating the formation of a complex between spec-
trin and dibucaine. The inset of Fig. 1 shows characteristic
£uorescence spectra of spectrin alone and in the presence of
varying concentrations of dibucaine. Fig. 2 shows the plot of
the extent of £uorescence quenching as the function of dibu-
caine concentration due to the association of dibucaine and
spectrin. The nature of the curve shows a non-cooperative
Fig. 1. Binding isotherm (£uorescence intensity at 340 nm versus li-
gand concentration) for the interaction of spectrin (0.1 WM) with di-
bucaine in 20 mM Tris^HCl, 50 mM NaCl bu¡er, pH 7.4 at 25‡C.
The excitation wavelength is 295 nm. Inset show the £uorescence
emission spectra (Vex = 295 nm) of 0.1 WM spectrin alone (solid
line), upon addition of 12 WM dibucaine (dashed line) and 30 WM
dibucaine (dotted line).
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type of binding. The dissociation constant (Kd) was deter-
mined by non-linear curve ¢t analysis described earlier [28].
The inset of Fig. 2 shows a representative double reciprocal
plot of 1/vF against 1/(Cd3Cs) to estimate the vFmax. A Kd of
35 WM was estimated for dibucaine binding to spectrin and
was independent of ionic strength of the bu¡er, in the pres-
ence of both low and high concentrations of NaCl (Table 1).
The thermodynamic parameters, e.g. changes in free energy,
enthalpy and entropy, were evaluated from the variation of
the apparent binding constant with temperature, the Van’t
Ho¡ plot. Fig. 3 shows a representative Van’t Ho¡ plot of
lnKapp against 1/T for the interaction of dibucaine with spec-
trin. Table 2 summarizes the thermodynamic parameters as-
sociated with the binding of dibucaine and spectrin. The in-
teraction is exothermic indicating the enthalpy-driven nature
of the interactions between the local anesthetic and the skel-
etal protein. Fig. 4 shows representative CD spectra of spec-
trin in the presence and absence of the local anesthetic. It
shows a signi¢cant change in the shape and intensity of the
near-UV CD spectra of spectrin upon binding to dibucaine.
However, the far-UV CD spectrum, shown in the inset of Fig.
4, indicated no signi¢cant change in the characteristic K-heli-
cal structure of spectrin upon association with dibucaine. The
results from CD spectroscopic studies in the far-UV and near-
UV regions indicate that there is a change in the tertiary
structure of the protein upon binding of dibucaine without
any signi¢cant alteration in the polypeptide backbone of the
protein.
4. Discussion
Spectrin has a number of tryptophan residues spread over
the entire length of the dimer. It is noteworthy that the 106
amino acid long repeat units in spectrin have tryptophans
strongly conserved at the 45th residue and partially conserved
at the 11th residue [29,30]. The tryptophans in these positions
represent more than 60% of the total tryptophans in the spec-
trin dimer. The fact that tryptophans are distributed over the
entire molecule and yet are localized in the same position in
each domain makes them convenient intrinsic £uorescence
reporter groups for monitoring conformational changes in
spectrin that contribute to its elastic deformability exhibited
in physiological conditions [31]. Ovine erythroid spectrin, used
Fig. 2. Plot of the extent of dibucaine-induced quenching vs. con-
centration of dibucaine for the evaluation of dissociation constant
of the association of dibucaine with spectrin (0.1 WM) in 20 mM
Tris^HCl, 50 mM NaCl bu¡er, pH 7.4 at 15‡C. Inset show the cor-
responding double reciprocal plot of 1/vF against 1/(Cd3Cs) to
evaluate the vFmax.
Table 1
Dissociation constant (Kd) for the interaction of dibucaine with ery-
throid spectrin in 20 mM Tris^HCl, 50 mM NaCl, pH 7.4 at 25‡C
Ligand Salt Kd (WM)
Dibucaine 0.05 M NaCl 32
1.0 M NaCl 37
2.0 M NaCl 35
Fig. 3. Van’t Ho¡ plot for the interaction of spectrin (0.1 WM) with
dibucaine in 20 mM Tris^HCl, 50 mM NaCl bu¡er, pH 7.4.
Fig. 4. Near-UV CD spectra (250^310 nm) of spectrin (3 WM) alone
(solid line) and in the presence of 120 WM dibucaine (dotted line) in
20 mM Tris^HCl, 50 mM NaCl bu¡er, pH 7.4 at 25‡C. Inset shows
the far-UV CD spectra (200^250 nm) of spectrin (1.5 WM) alone
(solid line) and in the presence of 40 WM dibucaine (dotted line) in
20 mM Tris^HCl, 50 mM NaCl bu¡er, pH 7.4 at 25‡C.
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in this study, has structural and self-associating properties
that are indistinguishable from those of human and bovine
spectrin [32]. Spectrin contains a unique binding site for hy-
drophobic £uorescence probes such as Prodan and pyrene
[33,34]. Spectrin also contains a large number of binding sites
for fatty acids and its derivatives [35,36], phospholipids [37],
ATP [28] and the DNA binding antitumor antibiotics chro-
momycin and mithramycin [25] along the length of the large
worm-like protein molecule.
Fluorescence and CD studies indicate the binding of dibu-
caine to spectrin. An absence of change in the CD spectrum of
spectrin in the wavelength region between 200 and 250 nm in
the presence of dibucaine suggests that the association does
not perturb the helical backbone structure of spectrin. Binding
of dibucaine proximal to the spectrin tryptophan residues
could lead to potential £uorescence energy transfer between
dibucaine and tryptophan which is manifested in the quench-
ing of tryptophan (donor) £uorescence. An estimate of the
stoichiometry of binding showed about 200 dibucaine mole-
cules to be associated with a spectrin dimer (Fig. 2), also
indicated energy transfer to be one of the most plausible
mechanisms through which the quenching takes place. How-
ever, alteration of the tertiary structure in spectrin also ap-
pears plausible when we compare the near-UV CD spectra of
spectrin in the absence and presence of the local anesthetic
since the bands in the near-UV CD spectrum of the protein
originate from the absorption by the aromatic side chain of
Phe, Trp, and Tyr. The linear nature of the Van’t Ho¡ plot
(Fig. 3) indicates that the association does not lead to any
major reshu¥ing of the two spectrin subunits. Favorable
non-covalent interactions leading to a negative change in en-
thalpy are a feature of the spectrin^dibucaine association. The
speci¢c nature of this interaction is indicated from the obser-
vation that the a⁄nity constant for the association is insensi-
tive to increases in ionic strength (Table 1).
One interesting aspect of the present work is that the
quenching of spectrin tryptophan £uorescence and the change
in the near-UV CD are only observed with the quinoline-
based tertiary amine local anesthetic dibucaine. Similar
changes were not observed in the benzene-based tertiary
amine local anesthetics procaine, tetracaine and lidocaine in-
dicating no binding of these local anesthetics to spectrin. The
kinetic and electron microscopic studies of the e¡ects of pro-
caine, tetracaine and dibucaine on the polymerization and
depolymerization of the microtubules indicated similar di¡er-
ential behavior of the benzene-based procaine and tetracaine
with that of the quinoline-based dibucaine. While procaine
and tetracaine were found to increase the rates of tubulin
polymerization at 24‡C and of microtubule depolymerization
at 4‡C as a linear function of the concentration of the local
anesthetics, the quinoline-based dibucaine, on the other hand,
showed a linear decrease in the tubulin polymerization and
microtubule depolymerization rates [17]. The interaction of
eight local anesthetics with cytochrome oxidase, chosen as a
membrane model protein, has been earlier studied with £uo-
rescence techniques using quinacrine as a £uorescent probe
indicating the existence of hydrophobic interactions with a
non-polar region of the cytochrome oxidase complex [7].
The stoichiometry and dissociation constants for the interac-
tion of tetracaine with chloroform-released mitochondrial
ATPase, determined from the enhancement of tetracaine £uo-
rescence intensity upon binding, indicated a single class of a
large number of approximately 60 thermodynamically equiv-
alent binding sites on the ATPase for tetracaine with a disso-
ciation constant of 4.9U1034 M at 25‡C [38]. The present
work reports for the ¢rst time the binding of the quinoline-
based local anesthetic, dibucaine to the membrane skeletal
spectrin associated with the binding dissociation constant of
3.5U1035 M at 25‡C, an order of magnitude stronger than
that of the benzene-based tetracaine with the ATPase. Our
results also indicate a possible di¡erence in the anesthetic
potentials between the quinoline-based dibucaine and the ben-
zene-based tetracaine, procaine and lidocaine in terms of
binding to the membrane skeletal protein spectrin.
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